HomeRGLS • NASDAQ
add
Regulus Therapeutics Inc
Nakaraang pagsara
$1.52
Sakop ng araw
$1.45 - $1.54
Sakop ng taon
$1.08 - $3.79
Market cap
96.92M USD
Average na Volume
414.60K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 14.19M | 81.62% |
Net na kita | -14.06M | -79.73% |
Net profit margin | — | — |
Kita sa bawat share | -0.21 | 47.50% |
EBITDA | -15.12M | -87.38% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 87.31M | 183.64% |
Kabuuang asset | 93.76M | 148.40% |
Kabuuang sagutin | 6.96M | -26.67% |
Kabuuang equity | 86.80M | — |
Natitirang share | 65.50M | — |
Presyo para makapag-book | 1.14 | — |
Return on assets | -38.43% | — |
Return on capital | -40.53% | — |
Cash Flow
Net change in cash
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -14.06M | -79.73% |
Cash mula sa mga operasyon | -9.45M | -50.53% |
Cash mula sa pag-invest | 18.64M | 442.72% |
Cash mula sa financing | 56.00K | -80.49% |
Net change in cash | 9.25M | 180.94% |
Malayang cash flow | -4.32M | -55.64% |
Tungkol
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Wikipedia
Itinatag
Set 2007
Website
Mga Empleyado
32
